Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 12/12/2018
SIETES contiene 92610 citas

 
 
 1 a 20 de 214 siguiente >>
Presentar resultados
Seleccionar todas
1.Tiene citas relacionadas Cita con resumen
Wiktor SZ, Scott JD. What is the impact of treatment for hepatitis C virus infection?. Lancet 2017;390:107-9. [Ref.ID 101668]
2. Cita con resumen
Anónimo. Rifaximine et encéphalopatie hépatique. Prescrire 2017;37:175-6. [Ref.ID 101454]
4. Cita con resumen
Anónimo. EMA advisory committee conditionally approves obeticholic acid. DIA Daily 2016:4. [Ref.ID 100812]
5. Cita con resumen
Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, Abu-Raddad LJ, Assadi R, Bhala N, Cowie B, Forouzanfour MH, Groeger J, Hanafiah KM, Jacobsen KH, James SL, MacLachlan J, Malekzadeh R, Martin NK, Mokdad AA, Mokdad AH, Murray CJL, Plass D, Rana S, Rein DB, Richardus JH, Sanabria J, Saylan M, Shahraz S, So S, Vlassov VV, Weiderpass E, Wiersma ST, Younis M, Yu C, El Sayed Zaki M, Cooke GS. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 2016;388:1081-8. [Ref.ID 100744]
6. Cita con resumen
Farmakiotis D, Zeluff B. Metronidazole-associated encephalopathy. N Engl J Med 2016;374:1465. [Ref.ID 100230]
7. Cita con resumen
Anónimo. FDA Advisory Panel unanimously recommends approval of new liver drug. FDA U.S. Food and Drug Administration 2016:2. [Ref.ID 100108]
8. Cita con resumen
Curry MP, O'Leary JG, Bzowei N, Muir AJ, Korenblat KM, Fenkel JM, Reddy KR, Lawitz E, Flamm SL, Schiano T, Teperman L, Fontana R, Schiff E, Fried M, Doehle B, An D, McNally J, Osinusi A, Brainard DM, McHutchison JG, Brown RSJr, Charlton M, ASTRAL-4 Investigators. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 2015;373:2618-28. [Ref.ID 99805]
9. Cita con resumen
Anónimo. FDA drug safety communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie. FDA U.S. Food and Drug Administration 2015:22 de octubre. [Ref.ID 99573]
10. Cita con resumen
Burton BK, Balwani M, Feillet F, Varic I, Burrow TA, Grande CC, Coker M, Consuelo-Sánchez A, Deegan P, Di Rocco M, Enns GM, Erbe R, Ezgu F, Ficicioglu C, Nightingale S, Peters H, Scarpa M, Schwab O, Smolka V, Valayannopoulos V, Wood M, Goodman Z, Yang Y, Eckert S, Rojas-Caro S, Quinn AG. A phase 3 trial of sebelipase alfa in lysosomal acid lipase deficiency. N Engl J Med 2015;373:1010-20. [Ref.ID 99532]
12. Cita con resumen
Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ari ZB, Zhao Y, Brown DD, Wan SH, DiNubile MJ, Nguyen B-Y, Robertson MN, Wahl J, Barr E, Butterton JR. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 2015;163:40-51. [Ref.ID 99335]
13. Cita con resumen
McCarthy M. Lawsuit seeks access to data from hepatitis C drug trial. BMJ 2015;350:h3564. [Ref.ID 99222]
14.
Muir AJ, Poordad F, Lalezari J, Everson G, Dore GJ, Herring R, Sheikh A, Hézode C, Pockros PJ, Tran A, Yozviak J, Neau N, Ramji A, Stuart K, Thompson AJ, Vierling J, Freilich B, Cooper J, Ghesquiere W, Yang R, McPhee F, Hughes EA, Swenson ES, Yin PD. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA 2015;313:1736-44. [Ref.ID 99085]
15.Tiene citas relacionadas Cita con resumen
Kohli A, Osinusi A, Sims Z, Nelson A, Meissner EG, Barrett LL, Bon D, Marti MM, Silk R, Kotb C, Gross C, Jolley TA, Sidharthan S, Petersen T, Townsend K, Egerson D, Kapoor R, Spurlin E, Sneller M, Proschan M, Herrmann E, Kwan R, Teferi G, Talwani R, Diaz G, Kleiner DE, Wood BJ, Chavez J, Abbott S, Symonds WT, Subramanian GM, Pang PS, McHutchison J, Polis MA, Fauci AS, Masur H, Kottilil S. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet 2015;385:1107-13. [Ref.ID 98987]
16.Tiene citas relacionadas Cita con resumen
Molina J-M, Orkin C, Iser DM, Zamora F-X, Nelson M, Stephan C, Massetto B, Gaggar A, Ni L, Svarovskaia E, Brainard D, Subramanian GM, McHutchison JG, Puoti M, Rockstroh JK, for the PHOTON-2 study team. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet 2015;385:1098-106. [Ref.ID 98986]
17.Tiene citas relacionadas Cita con resumen
Sulkowski M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, Kugelmas M, Murillo A, Weis N, Nahass R, Shibolet O, Serfaty L, Bourliere M, DeJesus E, Zuckerman E, Dutko F, Shaughnessy M, Hwang P, Howe AYM, Wahl J, Robertson M, Barr E, Haber B. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015;385:1087-97. [Ref.ID 98985]
18.Tiene citas relacionadas Cita con resumen
Lawitz E, Gane E, Pearlman B, Tam E, Ghesquiere W, Guyader D, Alric L, Bronowicki J-P, Lester L, Sievert W, Ghalib R, Balart L, Sund F, Lagging M, Dutko F, Shaughnessy M, Hwang P, Howe AYM, Wahl J, Robertson M, Barr E, Haber B. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015;385:1075-86. [Ref.ID 98984]
19.Tiene citas relacionadas
Foster GR. Shorter treatments for hepatitis C: another step forward?. Lancet 2015;385:1054-5. [Ref.ID 98983]
20.Tiene citas relacionadas
Naggie S, Kim AY. PHOTON-2: hope for patients with HIV and HCV co-infection?. Lancet 2015;385:1052-4. [Ref.ID 98982]
Seleccionar todas
 
 1 a 20 de 214 siguiente >>